Trodelvy® for the Treatment of Metastatic Urothelial Cancer
The Pharma Data
APRIL 14, 2021
Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. Premedicate with a two or three drug combination regimen (e.g., DRUG INTERACTIONS.
52 
Let's personalize your content